Share
.webp)
.webp)
.webp)
.webp)
Roger Dansey, M.D
Ottimo Pharma, an innovative biotech company focused on developing groundbreaking PD-1/VEGFR2 dual paratopic antibodies to improve the lives of cancer patients, has appointed Roger Dansey, M.D. to its Board of Directors.
Dr. Dansey is a highly respected leader in oncology research and drug development, with a track record of contributing to the clinical development and approval of several groundbreaking cancer therapies. His contributions include Keytruda (pembrolizumab), Xgeva/Prolia (denosumab), Zydelig (idelalisib), Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin), and Tukysa (tucatinib).
Currently, Dr. Dansey serves as an independent director on the boards of Inovio Inc. and Kronos Bio Inc., and as an advisor to Pfizer's Research and Development organization.
He previously held key roles as Chief Development Officer and Chief Oncology Officer at Pfizer Oncology and Chief Medical Officer and President of Research and Development at Seagen Inc.. Dr. Dansey’s career also includes senior leadership positions at Merck Inc., Gilead Sciences, and Amgen.
